Dr. Patrick Samir Chaftari, MD

Dr. Chaftari practices at The University of Texas MD Anderson Cancer Center in Houston, Texas, part of The University of Texas System.

Dr. Chaftari's NPI, 1356389027, was assigned on June 3, 2006. Dr. Chaftari graduated from St Joseph's University Medical School in 1992. Dr. Chaftari's Texas license number on file is M3975.

Dr. Chaftari's primary practice is The University of Texas MD Anderson Cancer Center, at 1515 Holcombe Blvd, Houston, TX 77030.

Dr. Chaftari's primary practice is The University of Texas MD Anderson Cancer Center in Houston, Texas, part of The University of Texas System. The medical group on file is Physicians Referral Service.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Chaftari practices. Vendor and product names are available with a free account.

Internal medicine is Dr. Chaftari's primary specialty in the NPI Registry, under taxonomy code 207R00000X. Dr. Chaftari is board certified in internal medicine by the American Board of Internal Medicine. Dmand AI has Dr. Chaftari's licenses on file in 2 states: Texas and Louisiana.

CMS data shows 188 Medicare services from Dr. Chaftari across 3 procedure codes in 2024, for 194 Medicare patients. Medicare paid $22,495 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 194 Medicare patients who saw Dr. Chaftari in 2024. The largest group is 65 to 74, with 107 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 12% are also on Medicaid. Their average risk score is 2.69, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Chaftari's median patient age at 69, with 56% women.

In 2024, Dr. Chaftari wrote 59 Medicare Part D claims for 44 patients. 92% of them were for generic drugs. CMS names the drug for 14 of them, across 1 drug with 11 or more claims each, at $83 in total drug cost. In 2022, CMS named 11 claims across 1 drug.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 84 out of 100 for Dr. Chaftari for performance year 2024, reported as part of a group. Dr. Chaftari accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 51 papers to Dr. Chaftari, published from 2014 to 2025. 2018 was the busiest year, with 10. The most frequent topics are Emergency Service, Hospital, COVID-19 and Cardiotoxicity. Dr. Chaftari has published most often in Am J Emerg Med. Dr. Chaftari's most frequent co-authors are Sai-Ching J. Yeung, MD, PhD, Demis N. Lipe, MD and Peter M. Lamie, DO.

Dmand AI links Dr. Chaftari to 1 clinical trial. Conditions studied include Leukemia, Mast-Cell and Mastocytosis, Systemic.

CMS Open Payments shows 5 general payments to Dr. Chaftari from 4 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 92% of the total. Cumberland Pharmaceuticals, Inc. paid the most, $153.

Dr. Chaftari graduated from St Joseph's University Medical School in 1992.

Dr. Chaftari is in network with 9 carriers, including Aetna, United Healthcare and Blue Cross Blue Shield of Michigan. PPO plans come from the most carriers, 6. Check the plan with the practice before a visit.